Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors

Pediatric Infectious Disease Journal

Volumn 22, Issue 1, 2003, Pages 70-76

  Van Rossum, Annemarie M C ^a   Gaakeer, Menno I ^a   Verweel, Gwenda ^a   Hartwig, Nico G ^a   Wolfs, Tom F W ^c   Geelen, Sibyl P M ^c   Lamberts, Steven W J ^b   De Groot, Ronald ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acquired immunodeficiency syndrome; Highly active antiretroviral therapy, growth; Human immunodeficiency virus; IGFs complexed to specific; Insulin growth factor I; Structurally homologous binding proteins

Indexed keywords

DIDANOSINE; HYDROCORTISONE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STAVUDINE; THYROXINE; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CATCH UP GROWTH; CHILD; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FREE THYROXINE INDEX; GROWTH DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; HYPOTHYROIDISM; INFANT; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY HEIGHT; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; FEMALE; GROWTH; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYDROCORTISONE; INFANT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; NELFINAVIR; SERUM ALBUMIN; THYROXINE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 0037231584     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200301000-00017     Document Type: Article

References (41)

1. Laue L, Pizzo PA, Butler K, Cutler GB Jr. Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome [see comments]. J Pediatr 1990;117: 541-5.
2. Tovo PA, de Martino M, Gabiano C, et al. Prognostic factors and survival in children with perinatal HIV-1 infection: The Italian Register for HIV Infections in Children. Lancet 1992; 339:1249-53.
3. McKinney RE Jr, Wilfert C. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine: AIDS Clinical Trials Group Protocol 043 Study Group. J Pediatr 1994;125(5 Pt 1):728-33.
4. Berhane R, Bagenda D, Marum L, et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics 1997;100:E7.
5. Matarazzo P, Palomba E, Lala R, et al. Growth impairment, IGF I hyposecretion and thyroid dysfunction in children with perinatal HIV-1 infection. Acta Paediatr 1994;83:1029-34.
6. Arpadi SM, Cuff PA, Kotler DP, et al. Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. J Nutr 2000;130:2498-502.
7. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection: The Italian Register for HIV Infections in Children and the Italian National AIDS. Registry. JAMA 2000;284:190-7.
8. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA Study Group. Lancet 1998;352:1725-30.
9. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
10. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8.
11. Van Rossum AM, Niesters HG, Geelen SP, et al. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in The Netherlands. J Pediatr 2000;136:780-8.
12. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997; 16:968-74.
13. Nadal D, Steiner F, Cheseaux JJ, Rudin C. Ritonavir promotes increased growth in HIV-infected children: Paediatric AIDS Group of Switzerland [Letter]. Aids 1998;12:2356-7.
14. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002;109:E25.
15. Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics 2001;107:E77.
16. Dreimane D, Nielsen K, Deveikis A, Bryson YJ, Geffner ME. Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2001;20:315-6.
17. Pollack H, Glasberg H, Lee E, et al. Impaired early growth of infants perinatally infected with human immunodeficiency virus: correlation with viral load. J Pediatr 1997;130:915-22.
18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
19. Rechler MM. Non-receptor-binding proteins for insulin-like growth factors and other cytokines: modulators of peptide action. In: Weintraub BD, ed. Molecular endocrinology, basic concepts and clinical correlations. New York: Raven Press, 1995:155-80.
20. Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations. J Pediatr 1997; 130:388-93.
21. Rolland-Cachera MF, Bellisle F, Sempe M. The prediction in boys and girls of the weight/height index and various skinfold measurements in adults: a two-decade follow study. Int J Obesity 1989;13:305-11.
22. van Wieringen JC, Roede MJ, Wit JM. [Growth diagrams for patient care]. Tijdschr Kindergeneeskd 1985;53:147-52.
23. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-9.
24. Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM. Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 1998;50: 166-76.
25. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age: official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR 1994;43:1-19.
26. LoPresti JS, Fried JC, Spencer CA, Nicoloff JT. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;110: 970-5.
27. Hirschfeld S, Laue L, Cutler GB Jr, Pizzo PA. Thyroid abnormalities in children infected with human immunodeficiency virus. J Pediatr 1996;128:70-4.
28. Blethen SL, Nachman S, Chasalow FI. Thyroid function in children with perinatally acquired antibodies to human immunodeficiency virus. J Pediatr Endocrinol 1994;7:201-4.
29. Geffner ME, Yeh DY, Landaw EM, et al. In vitro insulin-like growth factor-I, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr Res 1993;34:66-72.
30. Lala R, Palomba E, Matarazzo P, Altare F, Tovo PA. ACTH and cortisol secretions in children with perinatal HIV-1 infection. Pediatr AIDS HIV Infect 1996;7:243-5.
31. Oberfield SE, Kairam R, Bakshi S, et al. Steroid response to adrenocorticotropin stimulation in children with human immunodeficiency virus infection. J Clin Endocrinol Metab 1990;70:578-81.
32. Azzari C, Rossi ME, Resti M, et al. Changed levels of substance P and somatostatin in HIV-positive children. Pediatr Med Chir 1992;14:577-81.
33. Kaufman FR, Gomperts ED. Growth failure in boys with hemophilia and HIV infection. Am J Pediatr Hematol Oncol 1989;11:292-4.
34. Gertner JM, Kaufman FR, Donfield SM, et al. Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr 1994;124:896-902.
35. Schwartz LJ, St. Louis Y, Wu R, Wiznia A, Rubinstein A, Saenger P. Endocrine function in children with human immunodeficiency virus infection. Am J Dis Child 1991;145: 330-3.
36. Lepage P, Van de Perre P, Van Vliet G, et al. Clinical and endocrinologic manifestations in perinatally human immunodeficiency virus type 1-infected children aged 5 years or older. Am J Dis Child 1991;145:1248-51.
37. Jospe N, Powell KR. Growth hormone deficiency in an 8-year-old girl with human immunodeficiency virus infection. Pediatrics 1990;86:309-12.
38. Frost RA, Fuhrer J, Steigbigel R, Mariuz P, Lang CH, Gelato MC. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol (Oxf) 1996;44:501-14.
39. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956-62.
40. Ross R, Miell J, Freeman E, et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 1991;35:47-54.
41. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968;4:883-94.